COMMUNIQUÉS West-GlobeNewswire

Lighthouse Autism Center Opening New Autism Therapy Center in Asheboro, North Carolina
27/03/2026
ASHEBORO, N.C., March 27, 2026 (GLOBE NEWSWIRE) -- Lighthouse Autism Center (LAC), a leading provider of center-based autism therapy, is proud to announce the opening of a new autism therapy center in Asheboro, North [...]
SafeSpace Global to Attend NIC Spring Conference to Engage Senior Living and Healthcare Leaders
27/03/2026
Knoxville, TN., March 27, 2026 (GLOBE NEWSWIRE) -- SafeSpace Global Corp. (OTCID: SSGC) (SafeSpace Global or the Company), a leader in multimodal AI-powered safety and security solutions, dedicated to safety innovation [...]
Navigator Medicines Advances NAV-240 into Phase 2a and NAV-242 into the Clinic, Supported by New Positive Data Presented at American Academy of Dermatology (AAD) Annual Meeting 2026
27/03/2026
First Patient Dosed (FPD) in Phase 2a MAINSAIL Trial of NAV-240 in Hidradenitis Suppurativa (HS) Phase 1b Multiple Ascending Dose Study Demonstrates Favorable Profile for NAV-240 First Participant Dosed in Multi-Part [...]
First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement
27/03/2026
Inclusive of $80 million in proceeds from private placement by leading investors First Tracks Biotherapeutics to launch with $180 million in cash and two-year cash-runway SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- [...]
Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics
27/03/2026
Board sets spin-off distribution date for First Tracks Biotherapeutics: expected to occur April 20, 2026, pre-market Stockholders will receive one share of First Tracks Bio common stock for every one share of AnaptysBio [...]
Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update
27/03/2026
Anaptys to spin-off biopharma operations into First Tracks Biotherapeutics, with a target distribution date of April 20, 2026 Anaptys to manage the financial collaborations for Jemperli with GSK and imsidolimab with [...]
Axe Compute to Host Annual Report Conference Call
27/03/2026
Axe Compute to Report Fiscal Year 2025 Financial Results and File Annual Report on Form 10-K Conference call and webcast scheduled for April 1, 2026 PITTSBURGH, Pa., March 27, 2026 (GLOBE NEWSWIRE) -- Axe Compute ( [...]
Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs’ OneTest ™ Multi-Cancer Early Detection Blood Test
27/03/2026
State-Funded Screening Initiative Highlights Growing Public Sector Support for Innovative Cancer Detection Tools GAITHERSBURG, Md., March 27, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs , Inc. (Nasdaq: AIDX), an early market [...]
ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC
27/03/2026
Company to host a conference call and webcast on Tuesday, March 31, 2026 at 4:30 pm ET SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical [...]
Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2
27/03/2026
New Taipei City, Taiwan, March 27, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization [...]
Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones
27/03/2026
Experience From Brazilian and Australian Clinical Trials Positions the Company to Submit Investigational Device Exemption (IDE) to FDA for Novel CBGM Technology in Q2 2026 RUTHERFORD, N.J., March 27, 2026 (GLOBE [...]
Press Release: Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma
27/03/2026
Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma Recommendation based on positive results demonstrating comparable efficacy, [...]
Communiqué de presse : La formulation sous-cutanée de Sarclisa de Sanofi, administrée via un injecteur portable, est recommandée par le CHMP pour approbation dans l'UE dans le traitement du myélome multiple
27/03/2026
La formulation sous-cutanée de Sarclisa de Sanofi, administrée via un injecteur portable, est recommandée par le CHMP pour approbation dans l'UE dans le traitement du myélome multiple Recommandation fondée sur des [...]
OXB recognised as ‘Most Innovative CDMO (Cell & Gene)’ at 2026 CDMO Leadership Awards
27/03/2026
Oxford, UK – 27 March 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised with the ‘Most Innovative CDMO (Cell & Gene Therapy)’ award at the [...]
Vor Bio Announces $75 Million Private Placement with TCGX
27/03/2026
BOSTON, March 27, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a securities purchase [...]
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
27/03/2026
Company continues to evaluate strategic options to maximize shareholder value WATERTOWN, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative [...]
Satellos Reports 2025 Financial Results and Highlights Recent Company Progress
27/03/2026
Completed a US$57.2 million equity financing; commenced trading on the Nasdaq Global Market under the ticker “MSLE” on Feb. 6, 2026 Secured global regulatory clearances and initiated BASECAMP, a placebo-controlled Phase [...]
Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
27/03/2026
Company evaluating potential acquisitions and in-licensing opportunities to drive next phase of strategic development Cash position of $76.3 million as of December 31, 2025 expected to fund current operating plan beyond [...]
ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label
27/03/2026
Children were previously required to weigh ≥33 lbs. and <66 lbs. and be at least four years of age to receive neffy 1 mg dose - approval enables families of younger children within the weight range to access a needle [...]

Pages